Pomerantz Files Securities Class Action Against Quantum Biopharma

GlobeNewswire Inc.GlobeNewswire Inc.
|||1 min read
Key Takeaway

Pomerantz Law Firm files class action against Quantum Biopharma, alleging Canadian banks used spoofed orders to artificially depress stock price and buy shares at reduced rates.

Pomerantz Files Securities Class Action Against Quantum Biopharma

Pomerantz Law Firm has initiated class action litigation against Quantum Biopharma Ltd., alleging that major Canadian financial institutions engaged in market manipulation schemes designed to artificially depress the company's stock price. According to the complaint, CIBC World Markets, RBC Dominion Securities, and Royal Bank of Canada utilized spoofed sell orders—a practice involving the placement of non-genuine orders intended to deceive the market—to artificially suppress Quantum's share valuation while positioning themselves to acquire shares at artificially reduced prices.

The lawsuit contends that these trading practices misled other market participants and investors regarding genuine market demand for Quantum Biopharma securities. Affected investors face specific deadlines for participating in the class action and may be eligible to recover losses incurred during the relevant trading period. The firm has noted that shareholders who sustained losses are urged to contact legal counsel promptly to preserve their rights.

This litigation represents one of several ongoing enforcement actions targeting alleged market manipulation in Canadian securities markets. Investors holding Quantum Biopharma shares during the relevant period should review the complaint details and consult with legal representatives regarding eligibility and claim procedures.

Source: GlobeNewswire Inc.

Back to newsPublished Feb 17

Related Coverage

GlobeNewswire Inc.

Plug Power Faces Class Action Over DOE Loan Claims as April Deadline Looms

Plug Power faces class action lawsuit alleging false statements about DOE loans and hydrogen facilities. Investors have until April 3, 2026 to apply as lead plaintiffs.

PLUG
GlobeNewswire Inc.

BlackRock TCP Capital Hit by Class Action Over $19B NAV Collapse

BlackRock TCP Capital faces class action lawsuit after 19% NAV decline and 12.97% stock plunge. Investors must act by April 6 deadline.

TCPC
GlobeNewswire Inc.

Corcept Therapeutics Faces Class Action Over FDA Rejection; Stock Crashed 50%

Corcept Therapeutics faces securities fraud lawsuit after FDA rejected relacorilant application. Stock plummeted 50.4% following December rejection. Investor deadline April 21, 2026.

CORT
GlobeNewswire Inc.

Class Action Lawsuit Filed Against China Liberal Education Over Alleged $300M Pump-and-Dump Scheme

Class action lawsuit filed against China Liberal Education Holdings for alleged pump-and-dump scheme coordinating with scammers, resulting in $300M+ investor losses.

CLEUF
GlobeNewswire Inc.

METC Faces Class Action Over Brook Mine Claims; Lead Plaintiff Deadline Set for March 31

Ramaco Resources faces class action lawsuit over alleged false Brook Mine operational claims, with lead plaintiff deadline set for March 31, 2026.

METCMETCBMETCI
GlobeNewswire Inc.

Disc Medicine Stock Collapses on FDA Rejection; Law Firm Probes Securities Fraud

Pomerantz LLP investigates Disc Medicine ($IRON) for potential securities fraud after FDA rejected bitopertin drug application, triggering consecutive stock declines totaling over 28%.

IRON